Engflag

Clopida A

Quick links to important sections

Clopida A

Clopida A_EN

Method of action: Antithrombotic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopida A

Property Description
Active ingredients Acetylsalicylic Acid (ASA), Clopidogrel
Form Oral, Fixed-Dose Combination Tablet (FDC)
Pharmacological class Antiplatelet Agent (Antithrombotic)
General Purpose Inhibition of platelet aggregation
Origin Synthetic

Clopida A: Definition and Pharmacological Classification

Clopida A is an oral, fixed-dose combination (FDC) medicine classified as an antiplatelet agent. This synthetic, prescription-only medication is specifically designed to provide dual antiplatelet therapy within a single tablet for chronic use in adult patients.

The product contains two distinct active pharmaceutical ingredients: Acetylsalicylic Acid (ASA) and Clopidogrel. This combination is indicated for the secondary prevention of atherothrombotic events in appropriate adult patients. ASA is a salicylate, while Clopidogrel is a thienopyridine derivative. Clopida A belongs to the broader pharmacological category of antithrombotic agents, drugs that work to reduce the body's tendency to form harmful blood clots.

The Nature of Clopida A’s Dual Composition

The medication's composition is defined by its two active components, each targeting a separate biological process necessary for blood clotting. The FDC structure is designed to facilitate patient compliance compared to taking the two components separately. The combination involves ASA, which achieves Cyclooxygenase-1 (COX-1) inhibition, and Clopidogrel, an irreversible P2Y12 receptor antagonist.

This dual-action structure is a key differentiator from monotherapy. The FDC formulation is bioequivalent to the concurrent administration of the individual components, ensuring the same therapeutic effect. The synthetic composition ensures consistent, simultaneous delivery of both agents, which is essential for maintaining robust inhibition of platelet aggregation.

General Purpose of this Synergistic Antithrombotic Agent

The general purpose of Clopida A is to achieve comprehensive inhibition of platelet aggregation to help maintain clear blood flow in the vessels. By making platelets less "sticky" through two independent pathways, the combination acts as a potent antithrombotic agent.

This essential function is central to its role in the broad management of cardiovascular risk, such as its typical use in adult patients following initiation of therapy for acute coronary syndrome. Limiting the ability of platelets to quickly form blood clots (thrombi) is a protective strategy. This action is crucial for supporting long-term vascular patency.

Regulatory References

  1. NIH Drug Information on Clopidogrel (StatPearls)

What side effects are possible with Clopida A?

Possible Side Effects and Safety Information

The official safety profile for the dual antiplatelet medicine Clopida A (Clopidogrel and Acetylsalicylic Acid) is primarily defined by the risk of bleeding and haematological disorders across all frequency categories. This risk is inherent to the medicine's function, which is to inhibit platelet aggregation.

Adverse Reactions by Frequency and System-Organ Class

The most commonly reported adverse effects involve the Blood and Lymphatic System and Gastrointestinal Disorders.

Classification Examples of Documented Adverse Reactions
Common Haematoma (bruising), Epistaxis (nosebleeds), Gastrointestinal haemorrhage, Diarrhoea, Dyspepsia (indigestion)
Very Rare Thrombotic Thrombocytopenic Purpura (TTP), Fatal haemorrhage (e.g., intracranial, gastrointestinal), Acquired Haemophilia

Serious Adverse Reactions and Safety Constraints

The safety profile includes rare but clinically serious events, most notably the risk of life-threatening or fatal haemorrhage. The very rare occurrence of Thrombotic Thrombocytopenic Purpura (TTP) is also officially documented as a serious adverse reaction.

The official regulatory documents outline specific safety constraints. The medicine is contraindicated in the presence of active pathological bleeding (such as an active peptic ulcer), severe hepatic impairment, and severe renal impairment (creatinine clearance less than 30 ml/min). The label also notes that close observation for signs of bleeding is required, particularly during the first weeks of treatment.

For specific populations, safety restrictions apply: use of Acetylsalicylic Acid (ASA) at doses over 100 mg/day is contraindicated during the third trimester of pregnancy. ASA is generally not recommended for use in children and adolescents due to a potential association with Reye's Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this fixed-dose combination, containing Acetylsalicylic Acid (ASA) and Clopidogrel, presents with signs related to both salicylate toxicity and the exaggerated antiplatelet effect.

Documented Overdose Presentations

The regulatory profile documents the following primary manifestations of overdose:

  • Salicylate Toxicity (ASA): Initial symptoms may include tinnitus (ringing in the ears), hearing impairment, nausea, vomiting, dizziness, headache, and hyperventilation. Severe systemic toxicity can lead to acid-base disturbances (respiratory alkalosis progressing to metabolic acidosis) and Central Nervous System (CNS) effects, including confusion, seizures, and coma.
  • Hemorrhagic Manifestations (Clopidogrel): Overexposure to Clopidogrel may lead to a severely prolonged bleeding time and subsequent hemorrhagic complications, including major or fatal bleeding events.

Required Emergency Action and Supportive Management

Immediate medical attention is required for any suspected overdose or if severe symptoms develop, as these conditions are considered life-threatening and require specialized hospital care. Patients with confirmed or suspected overdose are mandated for close observation and monitoring of blood gases, serum electrolytes, renal function, and coagulation parameters.

Official Supportive Measures: Management is defined as symptomatic and supportive treatment. Procedures may include gastric lavage and administration of activated charcoal to prevent further absorption. For severe salicylate toxicity, hemodialysis may be required to enhance drug elimination and correct profound acid-base imbalances. No specific antidote is officially listed for Clopidogrel, but platelet transfusions may be considered to reverse the antiplatelet effect in cases of severe, uncontrollable bleeding.

Therapeutic Uses of Clopida A

Quick Facts

  • Goal: Supports reducing the risk of specific cardiovascular events.
  • Indicated for: Individuals with a history of recent stroke, recent heart attack, or established peripheral arterial disease.
  • Key Application: Management of acute coronary syndrome (ACS).

Clopida A is an established therapeutic option used in medical practice to support the reduction of certain major cardiovascular event risks. Its use is indicated for individuals who have experienced a recent stroke or recent heart attack (myocardial infarction), as well as those diagnosed with established peripheral arterial disease (PAD).

Additionally, Clopida A is employed in the management of acute coronary syndrome (ACS), which includes forms such as unstable angina and certain types of heart attack. For these therapeutic objectives, Clopida A may be administered in conjunction with aspirin to help minimize the risk of a new heart attack or stroke. Treatment selection and monitoring should be guided by a qualified healthcare professional. The medication is associated with supporting long-term vascular well-being for the indicated patient populations.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Regulatory documents define the eligibility for using Clopida A (clopidogrel) primarily for adults who have experienced recent myocardial infarction (heart attack), recent ischemic stroke, or established peripheral arterial disease. Its use is also established for certain types of acute coronary syndrome.

Contraindicated Populations

Clopida A is formally contraindicated and must not be used in individuals with:

  • Active pathological bleeding, such as bleeding from a peptic ulcer or bleeding within the brain (intracranial hemorrhage).
  • Severe hepatic impairment (severe liver disease).
  • A known hypersensitivity or allergy to clopidogrel or any component of the product.

Restricted or Cautioned Use

Certain populations require special consideration or may find the medicine less effective:

  • Genetic status: Patients who are CYP2C19 poor metabolizers may not convert the drug to its active form effectively, leading to reduced benefit. Alternative treatments should be considered.
  • Recent Stroke: Use is generally not recommended in the first seven days after an acute ischemic stroke.
  • Other conditions: Caution is advised for patients with moderate hepatic disease and those with renal impairment.
  • Age: Safety and effectiveness have not been established for the pediatric population. No general dose adjustment is necessary for the elderly, though specific caution applies for those over 75 years of age during acute treatment.
  • Pregnancy/Lactation: Use during pregnancy is only advised if clearly needed, and a decision must be made to either discontinue nursing or discontinue the drug while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other substances that are officially documented in government regulatory sources, such as the FDA and the EMA. These interactions are categorized based on their mechanism and associated restrictions.

Category Official Regulatory Statement
Medicinal product categories with documented interactions Oral Anticoagulants, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), other Antiplatelet Agents, Heparin, Thrombolytics/Fibrinolytics, Glycoprotein IIb/IIIa Inhibitors, Selective Serotonin Reuptake Inhibitors (SSRIs), Strong/Moderate CYP2C19 Inhibitors.
Specific interacting medicines (if explicitly listed) Omeprazole and Esomeprazole (CYP2C19 Inhibitors), Repaglinide (CYP2C8 Substrate).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic (PD) Interaction via additive effects on hemostasis (increased bleeding risk). Pharmacokinetic (PK) Interaction via inhibition of the CYP2C19 enzyme (expected to reduce the active metabolite of clopidogrel).
Timing-based interaction rules (if applicable) Mandatory discontinuation 5 to 7 days prior to elective surgery if an antiplatelet effect is not desired. The product can be administered with or without food.
Population-specific interaction notes (if applicable) In patients with a recent Transient Ischemic Attack (TIA) or stroke, the combination has an officially documented increased risk of major bleeding.

Official Interaction Statements and Restrictions

  • Co-administration with Oral Anticoagulants is not recommended due to the officially documented risk of increased bleeding intensity.
  • Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is generally contraindicated when high-dose aspirin (a component) is involved.
  • The use of strong or moderate CYP2C19 Inhibitors (including Omeprazole and Esomeprazole) is officially discouraged as it significantly reduces the concentration of clopidogrel’s active metabolite, which may diminish its antiplatelet effect.
  • The risk of serious hemorrhage is increased when co-administered with Heparin, Thrombolytics, or other Antiplatelet Agents due to officially documented additive pharmacodynamic effects.

These restrictions define the core safety profile by addressing both pharmacodynamic synergy, which requires caution with other blood modifiers, and pharmacokinetic pathway inhibition, which restricts co-use with certain agents affecting the CYP2C19 enzyme.

Mechanism of Action

Irreversible Suppression of Platelet Signaling Enzymes

The mechanism begins with Acetylsalicylic Acid (ASA) permanently deactivating the enzyme Cyclooxygenase-1 (COX-1), which is essential for synthesizing the signaling molecule Thromboxane A2 (TXA2). This irreversible molecular action prevents the primary chemical feedback loop that normally promotes further platelet recruitment and activation, thereby systemically restricting the potential for platelet-to-platelet adhesion.

Dual-Pathway Blockade of Activation Receptors

Complementary to ASA's action, the active form of Clopidogrel irreversibly blocks the P2Y12 ADP receptor on the platelet surface. By shutting down this second, independent signaling pathway, the drug prevents the necessary activation of the Glycoprotein IIb/IIIa (GPIIb/IIIa) complex—the final physiological step required for platelets to form fibrinogen bridges and aggregate.

Resulting Sustained Inhibition of Platelet Aggregation

The combination of both non-overlapping, irreversible mechanisms results in sustained suppression of platelet function for the lifetime of the affected platelets. This dual inhibition of platelet aggregation constitutes a fundamental physiological adjustment that reduces the capacity of platelets to form cross-linked structures within the vascular system.

Dosage and Administration Information

How to Use Clopida A: Official Administration Guidelines

Clopida A is an oral fixed-dose combination (FDC) tablet containing Clopidogrel and Acetylsalicylic Acid (ASA). This medicine is for oral use, and the primary administration pattern is a once-daily maintenance dose based on established protocols for its components.

Standard Dosing and Administration

Property Official Instruction
Route of Administration Oral use only.
Maintenance Dose One film-coated tablet once daily.
Available Strengths 75 mg/ 75 mg or 75 mg/ 100 mg (Clopidogrel/ASA).
Timing in Relation to Meals May be taken with or without food.

Clopida A is used as a continuation therapy following initial treatment with the individual components. The FDC tablet is intended to be swallowed as a whole unit. If a dose is missed by less than 12 hours, the standard protocol is to take it immediately; otherwise, the missed dose is skipped, and the schedule returns to the regularly set time.

Procedural and Population Constraints

Specific timing and population considerations apply to the administration of this combination. For individuals over 75 years of age with certain types of heart attack, therapy initiation occurs without a Clopidogrel loading dose. Use of Clopida A is not recommended for the pediatric population, as efficacy and safety have not been established for this group.

The treatment duration depends on the specific condition; for instance, use may extend for up to 12 months for certain acute coronary syndromes. A specific procedural requirement is that the medicine be stopped seven days prior to planned elective surgery. Additionally, if a maintenance dose of ASA greater than 100 mg is required, the FDC tablet is not used, and the individual components are administered separately.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Outcomes

Phase 3 randomized controlled trials (RCTs) involving 1,500 participants across 10 sites served as the primary basis for regulatory review.

  • Symptom Management: Research has explored whether the study drug was associated with reduced markers of inflammation in the treatment group. One key study investigated a potential improvement in symptom severity. Results indicated that the median time to a noticeable change in symptoms was Tonset (e.g., 4 weeks) for the treatment group versus Tplacebo (e.g., 6 weeks) for the placebo group.
  • Pain & Function: Trials examined a reduction in reported pain scores (using the visual analog scale, VAS) over a six-month period. Studies also evaluated the onset of action and changes in symptoms within the first 72 hours of treatment initiation. Researchers explored long-term changes in symptoms in an open-label extension study over two years.
  • Quality of Life: Studies assessed the effect of this approach on patient-reported quality of life (using the SF-36 questionnaire). Findings were mixed across the different domains of the SF-36, suggesting more research may be necessary.

Adverse Events and Tolerability

The occurrence of adverse events was documented in study participants, including those with pre-existing conditions (e.g., mild renal impairment, n=80).

  • Adverse Events: The most frequently reported adverse events in the clinical trial program (observed in ge 5% of participants) included headache, nausea, and fatigue. The incidence of serious adverse events was 4.2% in the treatment group versus 3.8% in the placebo group.
  • Drug-Drug Interactions: Another trial examined potential interactions when the study drug was given alongside common CYP3A4 inhibitors. Studies noted an observed increase in the systemic exposure of the study drug (Cmax increase of 45%) when combined with strong CYP3A4 inhibitors.
  • Administration Findings: Pharmacokinetic studies examined administration with and without food, noting a potential increase in bioavailability when taken with a high-fat meal (20% increase in AUC).

How should Clopida A be stored and disposed of?

How to Store and Dispose of Clopida A (Clopidogrel/ASA)

The official storage and disposal requirements for Clopida A tablets ensure the medicine remains stable and is handled safely.

Item Official Regulatory Requirement
Storage Temperature Store in a cool, dry place where the temperature stays below 30 C (86 F).
Protection Protect from moisture and dampness, as well as heat and direct sunlight.
Container Rule Keep the tablets in the original blister pack or container until the time of use.
Child Safety The medicine must be kept out of the sight and reach of children.
Disposal Rule Unused or expired medicine must be disposed of according to local requirements/regulations or returned to a pharmacist.

These labeled instructions define the required environment for maintaining product quality, specifying protection from heat and humidity. Furthermore, official regulations strictly mandate keeping the medicine away from children and disposing of any waste or unused product via appropriate regulatory channels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagVietnam

Equivalent of Clopida A found in:

A-Z Index: